#JENNIE# ‘You & Me’ [BORN PINK] WORLD TOUR STAGE MIX VIDEO HIGHLIGHT CLIP ▶️ #제니# #BLACKPINK# #블랙핑크# #SpecialSingle# #YouandMe# #BORNPINK# #WORLDTOUR# #STAGE_MIX_VIDEO# #HIGHLIGHTCLIP# #YG#

Seedance 2.5 at 1080p on OpenArt AI Prompt: Create a highly realistic, cinematic 30-second video for Seedance 2.5 featuring the same young Korean woman throughout the entire sequence, with consistent facial identity, body proportions, hairstyle, clothing, and natural skin texture. SUBJECT: A beautiful Korean woman in her early 20s with a natural, believable appearance. She wears an attractive everyday summer outfit: a fitted cropped T-shirt, stylish high-waisted casual shorts that are fashionable but natural for everyday streetwear, clean black sneakers, and a delicate simple necklace. Her black hair is loosely tied back with a few natural strands framing her face. Minimal makeup, realistic skin texture, subtle imperfections, expressive eyes and a relaxed, confident personality. SETTING: A charming older Korean neighborhood on a warm late-afternoon day. Narrow residential streets, low concrete houses, small local shops, parked bicycles and scooters, utility poles, faded signs, leafy trees, pedestrians in the distance and authentic Korean street details. The environment must feel genuinely lived-in rather than staged. VISUAL STYLE: Ultra-photorealistic cinematic documentary footage with the feeling of an authentic viral street-life video. Natural sunlight, realistic shadows, physically accurate reflections, believable skin and fabric textures, subtle lens imperfections, realistic depth of field and natural motion. High-quality modern capture with occasional handheld movement that feels human-operated, not artificially generated. No excessive beauty filter, plastic skin, CGI appearance or overly perfect composition. 30-SECOND SEQUENCE: 0–5 SEC: The woman walks casually through the narrow neighborhood street toward the camera, occasionally glancing around. A gentle breeze moves her hair and T-shirt naturally. The camera follows her from slightly behind and then moves alongside her. 5–10 SEC: She notices a tiny neighborhood snack shop and slows down. She looks through the open storefront, smiles naturally and walks closer. Capture small spontaneous gestures and realistic eye movement. 10–16 SEC: She orders a popular Korean street snack from the vendor. Show close-up details of the food being prepared: steam rising, utensils moving, sizzling sounds and realistic hand movements. She watches with genuine curiosity and exchanges a short laugh with the vendor. 16–22 SEC: She receives the hot snack, carefully blows on it because it is still hot, then takes her first bite. Her reaction is spontaneous and genuinely happy. Capture a brief close-up of her expression followed by a wider handheld shot. 22–27 SEC: She suddenly notices the camera filming her. She gives a playful surprised smile, steps slightly toward the lens and casually gestures as if inviting the viewer to follow her. Keep the interaction natural and unscripted-looking. 27–30 SEC: She turns and continues walking down the neighborhood lane. The camera follows for a few steps before naturally falling behind. End with her disappearing around a corner while the warm afternoon street ambience continues. CAMERA: Natural handheld cinematography, subtle operator movement, realistic walking camera motion, occasional focus adjustment, natural rack focus between the woman and surroundings, realistic motion blur, mild exposure adaptation and imperfect framing. Mix medium tracking shots, environmental wides, natural close-ups and over-the-shoulder shots. Avoid excessive camera movement or artificial cinematic effects. AUDIO: Authentic Korean neighborhood ambience only: footsteps, distant conversations, birds, passing scooters, bicycles, cooking sounds, light traffic, food sizzling, utensils and natural street noise. Include short natural Korean conversation between the woman and vendor, but keep dialogue casual and understated. NO background music. REALISM REQUIREMENTS: Maintain exact character identity across every shot. No face changes, age changes, hairstyle changes, clothing changes, duplicate people, warped hands, extra fingers, distorted food, floating objects, impossible shadows, inconsistent lighting, artificial facial expressions, unnatural walking, rubbery motion, text artifacts or CGI-looking environments. Every interaction must obey real-world physics. Make the entire sequence feel like genuine footage captured spontaneously in a real Korean neighborhood. FORMAT: 30 seconds, high-quality Seedance 2.5 generation, cinematic realism, natural 16:9 composition, detailed environmental textures, believable human motion, coherent continuity between shots, professional image quality while retaining the authenticity of real handheld street footage.

A TON OF THINGS HAPPENED IN THE STOCK MARKET TODAY. Here's a full recap: 1. Moderna $MRNA and Merck $MRK said their personalized mRNA cancer vaccine, intismeran, combined with Keytruda slowed melanoma recurrence and spread in a late-stage trial. The Phase 3 study was stopped at its first interim analysis after positive results, though detailed efficacy data have not yet been released. If the benefit holds, this would mark the first randomized Phase 3 validation of a personalized neoantigen cancer vaccine and could significantly expand the use case for mRNA technology beyond traditional vaccines. $MRNA surged 175% today, became the 2nd-best performing stock in the S&P 500 this year, and triggered an estimated $4.8B loss for short sellers. It was also the largest one-day percentage gain ever for an S&P 500 stock. 2. Crypto rallied sharply today as $BTC Bitcoin jumped roughly 8%, briefly touching about $70,000 for its biggest move since March, before settling near $68,500–$69,500. The move liquidated an estimated $1.4B–$1.7B of short positions and was driven by a mix of lower-yield pressure from Treasury buybacks, regulatory optimism, and today’s White House crypto meeting. $ETH Ethereum, $SOL Solana, and other major alts also traded higher, while crypto-linked stocks like Coinbase and Circle rallied. President Trump urged Congress to pass a “fair version” of the Clarity Act, said the U.S. should remain the leader in Bitcoin, crypto, prediction markets, and AI, and said he would listen to recommendations on whether the U.S. should accumulate more Bitcoin or crypto. Trump also said the CFTC is working to bring Hyperliquid into the U.S. in a fully compliant way, helping send HYPE higher. Overall, the tone was strongly pro-crypto, though the Clarity Act still faces political hurdles in the Senate. 3. Nebius $NBIS announced a proposed private offering of $4.5B of convertible senior notes. The offering includes $2.75B of notes due 2030 and $1.75B of notes due 2034, with an option for an additional $675M. Key terms, including interest rates and conversion prices, will be determined at pricing. Nebius was down 9.87% today. 4. U.S. national debt just crossed $40T, with the latest $10T added in roughly 4.5 years. The debt now equals about $116,481 per citizen and $360,794 per taxpayer, while the debt-to-GDP ratio sits around 122.7%. Federal spending is running at roughly $7.26T, compared to federal tax revenue of about $5.59T, leaving a federal budget deficit near $1.68T. Net interest on the debt is now running above $1.1T, making it one of the largest line items in the federal budget. 5. The U.S. Treasury announced it will double the size of long-term government debt buybacks after the rapid surge in Treasury yields. Repurchases of $2B will now increase to at least $4B, with the Treasury saying the move is meant to provide “liquidity support” for bonds maturing in 10 to 30 years as total U.S. debt nears $40T. The situation is like someone with a 30-year mortgage at 3.25% refinancing into a 1-year adjustable-rate loan at 5.75% because the market won’t absorb the longer-term debt cleanly. In other words, longer-duration, lower-cost debt is being replaced with shorter-term, higher-cost financing. Now apply that dynamic across trillions of dollars in U.S. government debt. That is the pressure Treasury is trying to manage as long-term yields keep rising. 6. Starlink is reapplying for India approval for its Gen 2 network, seeking authorization for nearly 30,000 LEO satellites operating at 340–615 km, including direct-to-device connectivity. India previously approved only Starlink’s 4,408-satellite Gen 1 network after rejecting the earlier Gen 2 application. The move comes as India is still finalizing D2D rules and satellite spectrum pricing, with Jio, Amazon Leo, and OneWeb also competing for the market, according to ET. 7. Goldman Sachs is preparing a roughly $1.15B junk bond to finance a Virginia data center leased to CoreWeave $CRWV. The deal is expected in September, with Goldman moving forward even as investors demand higher yields for AI infrastructure debt tied to CoreWeave. The financing comes after a separate $3.5B CoreWeave-backed deal recently priced at a 10% yield, underscoring how capital-intensive AI data center buildouts have become and how much credit markets are now focused on AI infrastructure risk. 8. The top 10 most active options today by contracts traded were $TSLA with 2.9M contracts, $NVDA with 2.6M contracts, $AAPL with 1.9M contracts, $AMZN with 1.0M contracts, $INTC with 932K contracts, $MU with 886K contracts, $MSTR with 789K contracts, $MSFT with 745K contracts, $SPCX with 694K contracts, and $META with 658K contracts. 9. Nvidia $NVDA has reportedly discussed investing in AI data supplier Mercor as part of a funding round that would value the startup at $20B, according to The Information. Mercor hires specialists across science, law, finance, and other fields to train and evaluate AI models, producing higher-quality data for complex tasks. Nvidia paid Mercor tens of millions of dollars last quarter and used its data to develop its two latest Nemotron models, with several Mercor employees now reportedly focused almost entirely on Nvidia-related work. The relationship is expanding as Nvidia invests more heavily in Nemotron, its open AI model family. Mercor has also worked with OpenAI, Google, and Anthropic, while annualized gross revenue reportedly reached $2B in June, double its level from the start of the year. 10. Webull $BULL reported Q2’26 revenue of $198.8M, beating estimates of $181M, up 51% YoY and 24% sequentially. Adjusted EPS came in at $0.12 versus $0.03 expected, up 140% YoY, while net income reached $24.4M and adjusted operating profit was $62.6M, representing a 31.5% margin. Trading-related revenue rose 66% YoY to $147.7M. Customer assets grew 79% YoY to $28.5B, registered users reached 28.2M, funded accounts hit 5.13M, equity notional volume rose 73% YoY to $279B, and options contract volume increased 68% YoY to 213M. Webull also launched Vega Analyst and announced the acquisition of Pi Securities in Thailand. 11. President Trump is reportedly set to reduce tariffs on automobiles imported from Canada from 25% to 15% as part of a broader trade deal, according to Bloomberg. The current tariff applies to the non-U.S. content of vehicles produced in Canada, and that same content provision is expected to apply under the new 15% rate. U.S. and Canadian negotiators have also discussed whether to expand the exemption to include additional content, though no final decision has been made. 12. U.S. margin debt fell by a record $85B in July to $1.42T, marking the largest monthly decline ever and the first monthly drop since March. For context, the prior record decline was $80B in January 2022, right as the bear market began. The pullback follows a massive $198B surge in margin debt across May and June, the largest two-month increase on record. Even after July’s historic decline, margin debt is still up $518B, or 58%, since the start of 2025. WALL STREET IS THE GREATEST SHOW ON EARTH.

Chief Scientific Officer Search at the AOI The Ackman Oxman Institute (AOI) is a new translational neuroscience, rehabilitation, and brain health institute in New York City founded to accelerate the translation of promising science to treating and curing patients. We are seeking a Chief Scientific Officer (CSO) who shares our ambition and recognizes that transformative advances depend on creative, independent scientists pursuing fundamental questions relevant to brain injury, degeneration, recovery, and rehabilitation. The CSO will help shape AOI's scientific identity, organization, and culture. We welcome the candidate's ideas about how best to organize the science and create an environment in which outstanding investigators can do their best work. Mandate Lead AOI's discovery science enterprise. Working with the Chief Translational Officer (CTO) and institute leadership, the CSO will define the research agenda, recruit and develop exceptional scientists, and determine the mix of investigator-led laboratories, collaborative teams, shared resources, and external partnerships best suited to the mission. The portfolio will support two complementary kinds of work: Patient-Anchored Translational Programs Research developed in anticipation of, as well as in response to, clinical observations. For example, a mechanistic program on mitochondrial delivery and bioenergetic rescue could inform a parallel clinical study of mitochondrial transplantation. Programs pursuing a defined path to patients will have clear milestones and criteria for advancement, redirection, or stopping, appropriate to their stage of development. Mission-Relevant Discovery Science Protected support for fundamental research on brain injury, repair, plasticity, and aging, led by investigators with intellectual independence. Major continuation or stop decisions will use a five-to-seven-year horizon, with ongoing scientific exchange and peer review to maintain rigor. This work can generate new therapeutic ideas and give AOI the depth to recognize and pursue discoveries arising from patient studies. The CSO will shape the balance between these forms of research and how they interact, with resources and review practices suited to each. Scientists will have the freedom to pursue original ideas within AOI's mission and contribute to a collaborative scientific community. Scope and Responsibilities Scientific Portfolio Define the research agenda with the CTO across acquired brain injury (stroke, TBI), and neurodegenerative and neuropsychiatric diagnoses as well brain health in aging. Build on AOI's initial priorities in bioenergetics/mitochondria, neuroinflammation, and neuroplastogens (devices or biologics that increase neuroplasticity), helping refine their scope, sequence, and organization. Identify promising mechanistic programs early so AOI is prepared to act on clinical discoveries, and welcome new ideas through a transparent scientific review process. Independent Discovery Recruit exceptional investigators and give them the resources and latitude to pursue fundamental questions relevant to AOI's mission. Develop peer review that evaluates scientific quality, originality, and contribution over an appropriate time horizon, recognizes the value of well-reasoned negative results, and protects intellectual independence. Scientific Infrastructure Determine which laboratory and measurement capabilities will best support the science, and which to build internally, share, or access through partnerships. Guide scientific use of shared resources, including GLP vivarium and GMP capabilities, in coordination with the CTO and Chief Regulatory Officer. Scientific Recruitment and Community Shape a recruitment and support model that attracts outstanding scientists with diverse approaches to discovery and collaboration. Explore joint or affiliated academic appointments and shared recruitment with New York City and regional universities and medical centers, where these strengthen recruitment, mentorship, and scientific exchange. Appointment arrangements will be developed with partner institutions and individual recruits. External Scientific Network Build a network of well-funded collaborations with academic laboratories in New York City and the region whose fundamental work is relevant to AOI's mission, so that AOI's discovery capacity extends well beyond its own walls. The Pershing Square MIND Prize community is a natural springboard for this network, though collaboration is not limited to prize recipients. Work with the founders on how the MIND Prize and AOI's basic research program should relate to each other over time. Scientific Quality Lead a collegial, rigorous scientific review process. For translational and later-stage preclinical programs, agree on clear milestones and advancement or stop criteria with program leaders and the CTO. For fundamental discovery, combine ongoing scientific dialogue with substantive peer review and five-to-seven-year continuation decisions. Uphold research integrity and reproducibility across all programs. External Standing Represent AOI's science to the field, to funders (NIH, ARPA-H, DoD, philanthropy), to scientific advisors, and to academic and industry partners. Relationship to the Chief Translational Officer The CSO and CTO are peers who connect discovery with development and clinical investigation. The CSO leads fundamental and exploratory preclinical research; the CTO leads regulated preclinical development, manufacturing, engineering, and trial readiness, and clinical studies. They jointly define the evidence needed to advance a program into development and review the portfolio together. Scientific collaboration continues as programs advance and clinical observations raise new research questions. First 6 Months •Develop a scientific strategy with the CEO, CTO, and board, including the proposed research organization, the balance of discovery and translation, initial priorities and resources, and a first set of anticipatory mechanistic programs. Agree on review practices that protect independent discovery and support timely development decisions. •Begin recruiting priority scientific leaders and independent investigators, with the mix and sequence of appointments shaped by the scientific strategy. Develop the support and affiliation arrangements needed to attract exceptional candidates. •Establish an agreed plan for laboratory capabilities and launch initial research using in-house resources or external partnerships as appropriate. Work with the CTO and clinical leadership to align research with patient studies and their readiness requirements. •Co-define the criteria for entering development with the CTO and begin well-funded collaborations with regional academic laboratories. Set the subsequent launch timetable around scientific priorities, recruitment, and facility readiness. Who We Are Looking For Essential •MD/PhD or PhD with a first-rank research record in neuroscience, immunology/neuroinflammation, bioenergetics, or a convergent field. •Experience building and leading a research organization (institute, department, biotech R&D unit, or focused research organization). •A track record of attracting outstanding scientists. •Enthusiasm for a patient-centered research model and for leading a team whose work spans the continuum from discovery to therapy development. Valued •Experience supporting independent investigators and collaborative research in academia, research institutes, or industry. •Scientific credibility in at least one of AOI's initial priority areas. •Comfort spanning biologics and device/neurotechnology science. •A demonstrated ability to protect creative discovery while guiding translational programs toward clear milestones. Practical AOI welcomes candidates from academia and industry who are excited to build the institute over the coming decade and beyond. The position is full-time in New York City. Candidates should be eager to focus their research leadership on the brain, recovery, and rehabilitation; any continuing research commitments should support that mission. Compensation will be competitive and will include the opportunity to participate in the value created through company formation at AOI. Leadership Team Engagement Works closely with the CTO as described above and with clinical leadership to connect research and patient studies. Engages the legal/regulatory team early on regulatory strategy, quality systems, and evidence requirements. Collaborates with the Chief AI Officer on data-rich study design and computational modeling, the COO on laboratory development and recruitment operations, and the CFO on scientific resource planning. Interested candidates should send their CV and a brief cover note to: CSO@aoi.org